---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-015996"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2023-05-05T23:59:59+00:00"
generated_at: "2026-06-15T16:54:39.431176+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ovid Q1 net loss $13.4M; cash $117.7M; adds ROCK2 program via Graviton

## Summary
- Net loss $13.4M ($0.19 loss per share) vs $16.1M ($0.23) in Q1 2022; operating expenses $15.0M.
- Cash, equivalents and marketable securities $117.7M as of March 31; expected runway into 2025.
- Collaboration with Graviton adds GV101 (ROCK2 inhibitor); Phase 2 for brainstem cavernous malformations targeted for 2024.
- OV329 Phase 1 on track with no safety signals; full data expected H1 2024; OV350 advancing preclinically.
- Concluding Columbia University genetic collaboration by year-end; out-licensing options explored.

## SEC filing metadata
- accession: 0001628280-23-015996
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2023-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000162828023015996/0001628280-23-015996-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000162828023015996/ovid-20230505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-015996
- JSON: https://secwatch.observer/filing/0001628280-23-015996.json
- Plain text: https://secwatch.observer/filing/0001628280-23-015996.txt

## Key facts
- Earnings Releases
  Ovid Therapeutics Inc. reported financial results for the first quarter ended March 31, 2023.
  - Period: the first quarter ended March 31, 2023
  - Result: reported results
  source text: On May 5, 2023, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing First Quarter 2023 Financial Results and Corporate Updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636651/000162828023015996/0001628280-23-015996-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.